is one brand name of numerous topical eye treatments used to address a variety of eye conditions. It does double-duty as an antibiotic to treat bacterial infections and as a steroid to reduce inflammation in the area surrounding the eye. Three powerful reasons to treat canine bacterial eye infections with Gentocin Durafilm GENTAMICIN SULFATE A broad-spectrum antibiotic with highly effective results against gram-positive bacterial and gram-negative bacterial infections of the eye. BETHAMETHASONE ACETATE A rapid-acting anti-inflammatory corticosteroid that provides symptomatic relief from bacterial, allergic, or traumatic tissue responses. DURAFILM An aqueous colloidal solution that coats the conjuctiva to maintain extended contact with the active, therapeutic ingredients A proven performer that goes on like a drop... coats like an ointment Prolonged contact, efficacy, and safety Unique formulation with a history of success Supports treatment and compliance
Dosage & Administration:
The topical application of GENTOCIN DURAFILM Ophthalmic Solution should, in each instance, be administered tomeet the specific needs of the individual case. One or two drops of the solution may be instilled into the conjuctival sac three or four times a day. Thereafter, the frequency of the dosage may be reduced but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.
GENTOCIN DURAFILM Ophthalmic Solution is indicated for the treatment of external eye infections and inflammation in dogs. Clinical reports indicate it is useful for the management of some cases of pigmentary keratitis and pannus. Temporary remission of some of the pathological lesions of the aforementoned conditions have been noted following therapy with GENTOCIn DURAFILM Ophthalmic Solution.
Corticosteroids are contraindicated in initial treatment of corneal ulcers. GENTOCIN DURAFILM Ophthalmic Solution is contraindicated in ocular conditions where there is a deep ulceration without vascularization and in conditions of viral origin before healing has commenced.
Not for human use. Keep this and all drugs out of the reach of children. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnanacy have produced cleft palate. Other congenital anomalies including deformed forelegs, phocomelia, and anssarca have been reported in offspring of dogs which received corticosteroids during pregnancy.
The antibiotic sensitivity of the infective organism in bacterial should be determined rior to the use of this preparation. The preparation is contraindicated in the case of nonsusceptible microorganisms. In deep-seated infections or when systemic infection threatens, specific systemic antibiotic or sulfonamide theraphy should be employed. Extended use of topical corticosteroids may cause incresed intraocular pressure in susceptible patients. In prolonged therapy, it is advisable to measure introcular pressure. In human medicine, in diseases that cause thinning of the cornea, perforation has been known to have occured with the use of topical steroids. Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibitation of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, theraphy with a rapidly acting corticosteroid should be considered in especially stressful